Fox Run Management, L.L.C. Uni Qure N.V. Transaction History

Fox Run Management, L.L.C.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$5.63 - $8.27 $21,534 - $31,632	3,825 Added 23.68%	19,978 $135,000
Q3 2023 Nov 07, 2023	BUY	$6.71 - $11.83 $108,386 - $191,089	16,153 New	16,153 $108,000
Q3 2021 Nov 15, 2021	SELL	$26.01 - $38.22 $204,126 - $299,950	-7,848 Closed	0 $0
Q2 2021 Aug 05, 2021	BUY	$29.97 - $37.17 $235,204 - $291,710	7,848 New	7,848 $242,000
Q2 2019 Jul 17, 2019	SELL	$52.76 - $82.19 $253,775 - $395,333	-4,810 Closed	0 $0
Q1 2019 Oct 17, 2019	BUY	$27.39 - $68.41 $131,745 - $329,052	4,810 New	4,810 $287,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.